Systematic Formulation–Process–Evaluation Approach and QbD Practice for Oral Dissolving Films (ODFs)

Systematic Formulation–Process–Evaluation Approach and QbD Practice for Oral Dissolving Films (ODFs)

Author:  Leyu Zhu,Sihan Meng

Affiliation: RSBM

Abstract

English:  (ODFs) provide swallow-free administration, pleasant mouthfeel, and fine-tunable dosing, accelerating their adoption across pharmaceuticals, nutrition, and oral-care markets. This paper presents a reusable Quality-by-Design (QbD) pathway for ODF development—TPP/TPQA → CQA → CMA/CPP → Design Space → Control Strategy—that systematizes material selection windows for film formers, plasticizers, solubilization and taste-masking systems, mucoadhesive/controlled-release polymers, and flavors/sweeteners; proposes three representative starter formulas; and links them to critical coating/drying/conditioning/packaging steps. Practical quality metrics are summarized for disintegration/dissolution, assay & content uniformity, mechanical properties, water activity, microbiology, seal integrity, and sensory, together with stability/packaging tactics to improve first-pass success and scalable tech transfer across diverse actives and use cases. ¹²

Keywords: oral dissolving films; film-forming polymers; taste masking; mucoadhesive controlled release; QbD; CQA; CPP; stability; unit-dose packaging

1. Introduction

ODFs deliver rapid onset, strong adherence, and portability through a “thin film → fast hydration → disintegration/adhesion” pathway. A QbD approach—combining risk assessment, statistical design, and in-line monitoring—creates a transferable development flow in which materials–process–packaging–stability co-optimize within a defined design space, outperforming empirical trial-and-error.¹³ The goal here is to provide materials-selection logic, process windows, critical quality attributes (CQAs), and verification methods as an actionable toolkit for project initiation and scale-up.²

2. Methods

This is a methods/practice-oriented narrative review that: (i) maps ODF formulation/process factors in QbD terms; (ii) distills implementable parameter ranges and QC checkpoints; (iii) offers three starter formulations plus DoE suggestions; and (iv) summarizes stability/packaging strategies and regulatory notes. No patient-level data or quantitative meta-analysis are included.¹²

3. Findings

3.1 Target Product Profile/Attributes (TPP/TPQA)

Administration path: immediate sublingual/buccal, mucoadhesive local therapy, or GI absorption.¹
Disintegration window: 10–30 s for immediate release; >3–20 min for mucoadhesive/extended release (use-case dependent).¹⁴
Unit mass/thickness: 20–1000 mg; typical dry thickness 60–150 μm.¹
Palatability: ≤slight bitterness, smooth mouthfeel; optional cooling and aroma.⁵⁶
Mechanical properties: tensile strength with adequate elongation; no edge cracking on peel.⁷
Stability: acceptable appearance/assay/dissolution from ambient up to 40 °C/75 %RH.⁸
Packaging: high-barrier unit pouches (e.g., PET/AL/PE) with easy-tear/easy-peel.⁹
Regulatory: compliant excipient lists, labeling/claims, GMP, and microbial limits for the target market.¹⁰

3.2 Materials System

3.2.1 Film-forming polymers (matrix)

Immediate-release: HPMC (E3–E6), PVA, pullulan, PVP, hydroxypropyl starch—chosen for fast swell-to-network breakup, smooth mouthfeel, and plasticizer compatibility.¹⁴
Mucoadhesive/extended: carbomer, cross-linked PVP, CMC-Na, chitosan, and poly(acrylic-acid) blends—to increase residence time and form gel layers with salivary electrolytes.¹¹
Layering/backing: IR layer + mucoadhesive layer; or drug layer + taste/mouthfeel layer; add an occlusive backing for unidirectional release when needed.¹¹¹²

3.2.2 Plasticizers & wetting aids

Plasticizers: glycerol, propylene glycol, sorbitol, PEG-400/600—lower Tg, improve flexibility/anticrack; excessive levels risk tackiness and delayed disintegration; typical optimization 15–30 % (w/w solids).¹⁴
Wetting/solubilizing aids: polysorbates/low-level surfactants and propylene glycol to accelerate hydration and early release.¹

3.2.3 Solubilization & solid dispersion

Approaches: amorphous solid dispersions, cyclodextrin inclusion, salt/ionization strategies, and micro-pH control. Objectives: increase instantaneous salivary availability, reduce bitter exposure, and prevent recrystallization.⁵⁶

3.2.4 Taste masking & mouthfeel engineering

Techniques: core–shell/multilayer structures, ion-exchange resins, microencapsulation, cyclodextrins, and flavor-sweetener-cooling synergies. User-experience cadence: pleasant perception at 3–5 s, full disintegration by 10–30 s.⁵⁶

3.2.5 Mucoadhesion & controlled release

Polymers: carbomer/chitosan/cross-linked PVP. Unidirectional release: single-side coat + EVA/PET backing to bias diffusion toward mucosa. Metrics: residence time, interfacial adhesion, mucosal flux.¹¹¹²

3.2.6 Other functional excipients

Sweetness/flavor/cooling: sucralose, acesulfame-K, aspartame, menthol, cooling esters.
Stabilization: antioxidant/antimoisture systems (e.g., citrate buffers, desiccants) and anti-recrystallization agents.
Preservation: sodium benzoate/potassium sorbate where permitted and sensory-acceptable.¹⁰

3.3 Process & Critical Process Parameters (CPPs)

Solution make-up: aqueous or aq-alcohol; allow full polymer swelling before adding plasticizers and actives/flavors; viscosity 1000–5000 mPa·s is coatable.¹³
Deaeration/filtration: vacuum or ultrasonic to avoid bubbles/pinholes.¹³
Coating: comma-bar/slot-die/doctor-blade; compute wet thickness from target dry thickness and solids (with shrinkage).¹³
Drying curve: staged temperatures (e.g., 40→60→75 °C) to avoid case-hardening/inner collapse; control residuals and internal stress.¹³
Conditioning: 25–35 °C, 40–60 %RH for plasticizer/water redistribution and mechanical stabilization.¹³
Slitting/die-cutting: minimize burrs and hold tight dimensional tolerances; in-line weight checks.¹³
Unit packaging: heat-seal high-barrier laminate; verify seal strength and leak integrity; ensure easy-tear/easy-peel design.⁹

Typical CPPs: solution viscosity; coating speed/gap; drying temperature/airflow/residence; conditioning time/RH; seal temperature/pressure.¹³

3.4 CQAs & Methods

Appearance/dimensions: visual + machine vision.
Thickness & mass variation: micrometer/β-gauge; engineering target RSD ≤ 5 %.⁷
Assay & content uniformity (AV): HPLC/UPLC per pharmacopoeia.¹⁰
Disintegration/dissolution: simulated saliva (pH 6.8, low/no surfactant); flow-through cell if needed; target 10–30 s or product-specific profiles.¹⁴
Mechanical properties: tensile and bend tests.⁷
Moisture & water activity (a_w): Karl Fischer and water-activity meter.⁸
Microbiology & preservative efficacy: per target-market standards.¹⁰
Package integrity: dye ingress, vacuum-decay, or helium leak; evaluate WVTR/OTR for barrier performance.⁹
Sensory & acceptability: sweetness, cooling, aftertaste, irritation, and overall liking—panel/consumer tests.⁶

3.5 Stability & Packaging Strategy

Chemical stability: pH buffering, antioxidant pairing, light protection.⁸
Physical stability: anti-recrystallization, plasticizer-migration control, and Tg–humidity balance.⁸
Moisture management: low-a_w formulation + high-barrier unit pack + desiccant secondary.⁹
Stability plans: 40 °C/75 %RH, 30 °C/65 %RH, 25 °C/60 %RH with trending of assay, dissolution, palatability, and appearance.⁸

3.6 Representative “Starter” Formulas (dry-basis ranges; to be optimized)

Starting windows; refine with the active’s physicochemistry and regulatory constraints.

A. Immediate-release functional (stimulation/sleep aid/vitamins)

Film former HPMC/Pullulan 60–75 %; plasticizer (glycerol/PG) 15–25 %; sweetness+cooling 3–6 %; buffer/solubilization 2–5 %; active to target dose (fast-dissolving actives typically ≤ 20–50 mg per film). Target: 10–20 s disintegration; smooth mouthfeel; moderate strength.¹⁴

B. Mucoadhesive local-therapy (ulcer/desensitizing/antimicrobial)
Mucoadhesive base Carbomer/XL-PVP/Chitosan 40–60 %; plasticizer 10–20 %; buffer & mucosal protectants 5–10 %; add backing if required. Target: 5–20 min residence; mucosa-directed release.¹¹¹²

C. “Fast + Sustained” bilayer
Top IR layer (HPMC/PVA) + bottom mucoadhesive (carbomer) with a middle isolation layer to prevent migration. Target: early peak within ≤ 5 min plus 30–60 min maintenance (active-dependent).¹¹¹²

3.7 DoE & Control Strategy

QRM identification: fishbone/FTA to identify CMAs/CPPs impacting CQAs.²
DoE: Box–Behnken/central-composite/mixture designs; factors (polymer ratio, plasticizer level, drying temperature, etc.); responses (disintegration time, tensile strength, AV).¹³
Multi-objective optimization: desirability to meet ≤ 30 s disintegration + ≥ X MPa strength + AV compliance concurrently.¹³
Control strategy: establish PAT (in-line thickness/weight), batch-release criteria, and auditable design-space documentation.²

image

4. Discussion

Key ODF challenges arise from cross-disciplinary coupling—polymer glass transition and plasticization, saliva hydrodynamics and pH, backing-driven interfacial adhesion, and drying stress/residuals—all shaping the balance of palatability–disintegration–strength–stability. Layered structures and unidirectional release reduce swallowed loss and improve mucosal flux; high-barrier unit packs plus in-line QC minimize scrap and variability. Future work should build IVIVC/IVRT models, quantify real-world adherence/outcomes, explore biodegradable backings, and digitize mass-customization for small-batch multi-strength production.¹¹¹²¹³

5. Conclusion

QbD-guided ODF development starts from TPP/TPQA to back-cast CQAs, then constructs an integrated design space across materials–process–packaging–stability. With taste/mouthfeel engineering, layering/backed unidirectional release, DoE-based optimization, and high-barrier unit packaging, teams can markedly improve first-pass success and reproducible scale-up, enabling high-quality, scalable ODF solutions for drug, nutrition, and oral-care applications.¹²¹³

image

Resources / References (superscripts map 1–14)

  1. Jacob S, Nair AB. Orodispersible films: current innovations and emerging trends in oral drug delivery. Pharmaceutics (review).

  2. ICH Q8(R2) Pharmaceutical Development; ICH Q9(R1) Quality Risk Management; ICH Q10 Pharmaceutical Quality System.

  3. Yu LX, Kopcha M. The future of pharmaceutical quality and the path to QbD. Int J Pharm (commentary).

  4. Ferlak J, Hlawacz I, Kucharska M, et al. Orodispersible films—state of the art, limitations and future perspectives. Pharmaceutics (review).

  5. Adamkiewicz L, Szymaszkiewicz A, Kozłowska J. Cyclodextrins as taste-masking agents in oral dosage forms. Pharmaceutics (review).

  6. Thakker P, et al. Taste masking of pharmaceutical formulations: technologies and trends. J Control Release (review).

  7. Centkowska K, et al. Homogeneity and mechanical properties of ODFs—impact of composition/processing. Pharmaceutics / Eur J Pharm Sci.

  8. General guidance on water activity (a_w) and stability for solid orodispersible systems (USP/Ph. Eur. texts and thin-film stability reviews).

  9. ASTM standards: F88 (seal strength), F1249 (WVTR), D3985/F1927 (OTR), F2338 (vacuum-decay leak).

  10. USP/Ph. Eur. chapters on microbial limits (e.g., USP <61>/<62>), preservative efficacy (USP <51>), and content uniformity (USP <905>).

  11. Madhav NVS, Shakya AK, et al. Mucoadhesive drug delivery systems: formulation and evaluation (review).

  12. Grilc B, Šturm L, Planinšek O, et al. Backing layers and unidirectional release from buccal films. Pharmaceutics (study/review).

  13. QbD/DoE toolkits for film casting and scale-up (Box–Behnken, central composite, mixture designs)—textbooks and pharmaceutics reviews.

  14. Practical ODF targets for <30–60 s disintegration and IR polymer systems—ODF formulation reviews in Pharmaceutics / Eur J Pharm Biopharm.


Previous：Storage Method of Melatonin Oral Dissolving Films

Next：Mechanisms of Action of Oral Dissolving Films(ODFs)